公开(公告)号：US20240245859A1

公开(公告)日：2024-07-25

申请号：US18406558

申请日：2024-01-08

Applicant: Think N Kreate Limited

Inventor： Choi Ting LAU

IPC: A61M5/172 ,  A61M5/142 ,  A61M5/168

CPC classification number: A61M5/1723 ,  A61M5/14232 ,  A61M5/16813 ,  A61M2202/0486

Abstract: An automated, closed-loop gravity infusion system including a fluid source, a drop counter operatively engaged with a drip chamber of the fluid source, a roller clamp functionally linked with the drop counter, a processor operably engaged with the roller clamp, and a human-machine interface (HMI) functionally linked with the processor. Patient data is accessed by the HMI. The system utilizes the patient data and data from the drop counter to determine an appropriate roller clamp position. The drop counter continuously monitors the drip chamber's drip rate and feeds the data to the processor which then analyzes the data and automatically adjusts the roller clamp's position to provide an appropriate fluid dosage to the patient. The HMI is functionally linked to a remote centralized computing system configured to simultaneously monitor several identical systems, each of which is being used to infuse a different patient.

公开(公告)号：US12036344B2

公开(公告)日：2024-07-16

申请号：US17097299

申请日：2020-11-13

Applicant: FRESENIUS MEDICAL CARE HOLDINGS, INC.

Inventor： Peter Kotanko ,  Xia Tao ,  Mia G. Garbaccio ,  Jeffrey Hymes ,  Stephan Thijssen ,  Nadja Grobe ,  Leticia M. Tapia Silva ,  Dinesh K. Chatoth

IPC: A61M1/28 ,  A61M1/00 ,  A61M1/16

CPC classification number: A61M1/1619 ,  A61M1/1643 ,  A61M1/28 ,  A61M1/69 ,  A61M2202/0439 ,  A61M2202/0486 ,  A61M2205/18 ,  A61M2205/3327 ,  A61M2205/3592 ,  A61M2205/583 ,  A61M2205/587

Abstract: An apparatus used in analyzing spent dialysate includes: at least one surface configured to accommodate a dialysate drain bag or drain line in a predetermined position; a light source positioned to emit light through the dialysate drain bag or drain line; and a light sensor positioned to sense light emitted by the light source through the dialysate drain bag or drain line.

公开(公告)号：US20240108809A1

公开(公告)日：2024-04-04

申请号：US18477365

申请日：2023-09-28

Applicant: Carol Ann Metz

Inventor： Carol Ann Metz

IPC: A61M5/315 ,  A61M5/32

CPC classification number: A61M5/31548 ,  A61M5/3287 ,  A61M2202/0486 ,  A61M2205/587

Abstract: The present invention is a self-injection pen. The self-injection pen has a needle, a medication cartridge, and a pen body. The needle and the medication cartridge are standard commercially available components that are suitable for injecting a liquid medication into the subcutaneous tissue layer of a human or animal body. The medication cartridge has a dose adjustor, and the pen body has an outer casing, a dose adjustment dial and an injector button. The needle is secured to the medication cartridge and allows a liquid medication to flow from the medication cartridge into the body of the user. The dose adjustor controls the amount of liquid medication being administered from the medication cartridge.

公开(公告)号：US20240066222A1

公开(公告)日：2024-02-29

申请号：US18269963

申请日：2021-12-08

Applicant: MEDTRUM TECHNOLOGIES INC.

Inventor： Cuijun Yang

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14248 ,  A61M2202/0486

Abstract: A drug infusion device with embedded power supply includes a drug reservoir, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel, connected with the screw, driving the screw to push the piston forward by rotation; a power supply, used to supply power to the infusion device, including a power supply shell, a battery cell, electrolyte and a cover plate; a frame, used to carry the drug reservoir, the driving wheel, the power supply and electrical connection terminals of specific components, the power supply is electrically connected to the electrical connection terminals of specific components to realize power supply to the infusion device; a case, including an upper case and a lower case, for accommodating the drug reservoir, the driving wheel, the power supply and frame.

公开(公告)号：US20230310742A1

公开(公告)日：2023-10-05

申请号：US18190572

申请日：2023-03-27

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Eric BENJAMIN ,  Jason O'CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  A61M5/168

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M5/16877 ,  A61M2205/3576 ,  A61M2205/52 ,  A61M2202/0486

Abstract: Disclosed are techniques, processes, systems, and programming code that enables users of automatic drug delivery devices to initiate the automatic drug delivery device for an initial use phase as well as implement changes that control the adjustment of target setpoints by a medication delivery algorithm used in the control of the automatic drug delivery device. During the initial use phase, the automatic drug delivery device may be based on the user's glucose control outcome without performing time consuming and frequent settings of sensor values as well as allowing users to remain substantially within range of any target setpoints. In addition, the disclosed techniques, processes, systems, and programming code enable users to have initial dosage settings automatically set without having to input what were previously considered fundamental inputs.

公开(公告)号：US20230218821A1

公开(公告)日：2023-07-13

申请号：US17998215

申请日：2021-05-07

Applicant: Eli Lilly and Company

Inventor： Amy Kathleen BARTEE ,  Ahmad Mohamad HAIDAR ,  Richard Earl JONES, Jr.

IPC: A61M5/172 ,  A61M5/168 ,  G16H20/17

CPC classification number: A61M5/1723 ,  A61M5/16877 ,  G16H20/17 ,  A61M2202/0486

Abstract: A system includes a controller that is in communication with a medication delivery device and that includes control logic. The control logic is operative to calculate a first filtered total daily dose (TDD) during an initial tracking phase based, at least in part, on a first set of insulin delivery doses and subject to a first set of rate limits. The control logic is also operative to calculate a second filtered TDD during a steady state tracking phase based, at least in part, on a second set of insulin delivery doses and subject to a second set of rate limits.

公开(公告)号：US20230166033A1

公开(公告)日：2023-06-01

申请号：US18071835

申请日：2022-11-30

Applicant: Tandem Diabetes Care, Inc.

Inventor： Dwight Lee ,  Christoper Jung ,  Amanda Lennard ,  Garrett Marin

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/172 ,  A61M5/14244 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2202/0486

Abstract: In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and/or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and/or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.

公开(公告)号：US20170189615A1

公开(公告)日：2017-07-06

申请号：US15462334

申请日：2017-03-17

Applicant: Bigfoot Biomedical, Inc.

Inventor： Mark C. Estes

IPC: A61M5/172 ,  A61M5/00 ,  A61M5/142 ,  A61K38/26

CPC classification number: A61M5/1723 ,  A61K38/26 ,  A61M5/003 ,  A61M5/14244 ,  A61M5/14248 ,  A61M5/24 ,  A61M2202/0486 ,  A61M2205/3561 ,  A61M2205/3584 ,  A61M2205/3592 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/8206 ,  A61M2230/201 ,  G06F19/3468 ,  G16H20/17

Abstract: Some embodiments a glucagon administration system can provide a suggested glucagon dosage based on one or more particular parameters (e.g., the user's recent blood glucose characteristics, a glucagon sensitivity value of the user, and other parameters). In some circumstances, the glucagon administration system can receive information indicative of the user's blood glucose level and suggest a glucagon dosage that is at least partially dependent upon a previously stored glucagon sensitivity for the user.

公开(公告)号：US09629901B2

公开(公告)日：2017-04-25

申请号：US14320863

申请日：2014-07-01

Applicant: Bigfoot Biomedical, Inc.

Inventor： Mark C. Estes

IPC: A61K9/22 ,  A61K38/26 ,  A61M5/00 ,  A61M5/172 ,  A61M5/24 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61K38/26 ,  A61M5/003 ,  A61M5/14244 ,  A61M5/14248 ,  A61M5/24 ,  A61M2202/0486 ,  A61M2205/3561 ,  A61M2205/3584 ,  A61M2205/3592 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/8206 ,  A61M2230/201 ,  G06F19/00 ,  G06F19/3468 ,  G16H20/17

Abstract: Some embodiments a glucagon administration system can provide a suggested glucagon dosage based on one or more particular parameters (e.g., the user's recent blood glucose characteristics, a glucagon sensitivity value of the user, and other parameters). In some circumstances, the glucagon administration system can receive information indicative of the user's blood glucose level and suggest a glucagon dosage that is at least partially dependent upon a previously stored glucagon sensitivity for the user.

公开(公告)号：USRE50075E1

公开(公告)日：2024-08-13

申请号：US17313401

申请日：2021-05-06

Applicant: Trustees of Boston University

Inventor： Edward R. Damiano ,  Firas H. El-Khatib

IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145 ,  A61M5/142 ,  A61M5/168 ,  G16H15/00 ,  G16H20/17

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61B5/4839 ,  A61M5/16827 ,  G16H15/00 ,  G16H20/17 ,  A61M2005/14208 ,  A61M2005/14296 ,  A61M2202/0486 ,  A61M2202/07 ,  A61M2205/3584 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2230/005 ,  A61M2230/201

Abstract: Apparatus and methods calculate and deliver doses of insulin and optionally glucagon into a subject. Online operation controls delivery of correction doses of insulin automatically in response to regular glucose measurements from a sensor, and offline operation calculates and delivers correction doses based on isolated glucose measurements and information gathered autonomously during preceding online operation. In another aspect, offline operation includes automatically calculating and administering meal doses based on information gathered autonomously during preceding periods of online operation. Both methods include generating relevant control parameters tailored to the individual and continually converged upon and potentially modulated during online operation. The control parameters are employed in real time during periods of offline operation to regulate glucose level without the need for user-provided control parameters such as correction factors and insulin-to-carbohydrate ratios.